肝细胞癌合并门静脉癌栓的临床评估进展
Progress in Clinical Evaluation of Hepatocellular Carcinoma Complicated with Portal Vein Tumor Thrombus
DOI: 10.12677/ACM.2022.12121604, PDF,  被引量   
作者: 王 雯, 别文海：青海大学研究生院，青海 西宁；青海大学附属医院肝胆胰外科，青海 西宁；周留馨, 王志鑫*：青海大学附属医院肝胆胰外科，青海 西宁
关键词: 肝细胞癌；门静脉癌栓；临床特点；危险因素；研究进展；Hepatocellular Carcinoma； Portal Vein Tumor Thrombus； Clinical Characteristics； Risk Factors； Research Progress
摘要: 肝细胞癌是临床中常见的恶性肿瘤疾病，因其临床症状隐匿，待发现时已经入中晚期，而门静脉癌栓是影响肝细胞癌患者预后的重要因素之一。门静脉癌栓其肿瘤学特征特性较强，极易发生肝外转移，并发门脉高压，导致消化道出血或肝衰竭，引起死亡。因此，在早期能够及时预测患者有无发生门静脉癌栓的风险并及时予以对症治疗就显得尤为重要。本文旨在回顾肝细胞癌合并门静脉癌栓相关文献，对肝细胞癌合并门静脉癌栓的临床特点及危险因素进行总结。
Abstract: Hepatocellular carcinoma (HCC) is a common malignant tumor in clinic. It has entered the middle and late stage because of its hidden clinical symptoms, and portal vein tumor thrombus is one of the important factors affecting the prognosis of patients with HCC. Portal vein tumor thrombus has strong oncological characteristics, which is prone to extrahepatic metastasis and portal hyperten-sion, resulting in gastrointestinal bleeding or liver failure, resulting in death. Therefore, it is partic-ularly important to predict the risk of portal vein tumor thrombus in early stage and give sympto-matic treatment in time. The purpose of this paper is to review the related literature of hepatocel-lular carcinoma with portal vein tumor thrombus and summarize the clinical characteristics and risk factors of hepatocellular carcinoma with portal vein tumor thrombus.
文章引用：王雯, 别文海, 周留馨, 王志鑫. 肝细胞癌合并门静脉癌栓的临床评估进展[J]. 临床医学进展, 2022, 12(12): 11129-11134. https://doi.org/10.12677/ACM.2022.12121604

参考文献

[1] 程树群, 吴孟超, 陈汉, 等. 肝癌伴门静脉癌栓形成与食管胃底静脉曲张程度及出血的关系[J]. 中华普通外科杂志, 2004, 19(5): 31-33.
[2] 吴孟超, 陈汉, 沈锋. 原发性肝癌的外科治疗5524例报告(英文) [J]. 中华外科杂志, 2001, 39(6): 4-8.
[3] Shim, J.H., Jun, M.J., Han, S., et al. (2015) Prognostic Nomograms for Prediction of Recurrence and Survival after Curative Liver Resection for Hepatocellular Carcinoma. Annals of Surgery, 261, 939-946. [Google Scholar] [CrossRef] 
[4] Zhu, K., Chen, J., Lai, L., et al. (2014) Hepatocellular Car-cinoma with Portal Vein Tumor Thrombus: Treatment with Transarterial Chemoembolization Combined with Soraf-enib—A Retrospective Controlled Study. Radiology, 272, 284-293. [Google Scholar] [CrossRef] [PubMed]
[5] Chen, S.P., Liu, B.X., Xu, J., et al. (2015) MiR-449a Suppresses the Epithelial-Mesenchymal Transition and Metastasis of Hepatocellular Carcinoma by Multiple Targets. BMC Cancer, 15, Article No. 706. [Google Scholar] [CrossRef] [PubMed]
[6] 中国医师协会肝癌专业委员会. 中国肝细胞癌合并门静脉癌栓诊疗指南(2021年版) [J]. 中华医学杂志, 2022, 102(4): 243-254.
[7] 王和平, 刘金贵. CT对门静脉系血栓与癌栓的诊断鉴别[J]. 昆明医学院学报, 2011, 32(6): 129-132.
[8] 程树群, 吴孟超, 程红岩, 等. 原发性肝癌门静脉癌栓生长特征的研究[J]. 中国现代普通外科进展, 2003, 6(2): 103-105.
[9] 孙保木, 罗明, 吴孟超. 门静脉癌栓及其治疗[J]. 肝脏, 2009, 14(1): 56-58.
[10] Ikai, I., Yamamoto, Y., Yamamoto, N., et al. (2003) Results of Hepatic Resection for Hepatocellular Carcinoma Invading Major Portal and/or Hepatic Veins. Surgical Oncology Clinics of North America, 12, 65-75. [Google Scholar] [CrossRef] 
[11] 程树群, 吴孟超, 陈汉, 等. 肝癌门静脉癌栓分型的影像学意义 [J]. 中华普通外科杂志, 2004, 19(4): 200-201.
[12] Cheng, S.Q., et al. (2007) Tumor Thrombus Types In-fluence the Prognosis of Hepatocellular Carcinoma with the Tumor Thrombi in the Portal Vein. Hepatogastroenterology, 54, 499-502.
[13] Shi, J., Lai, E.C., Li, N., et al. (2010) Surgical Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Annals of Surgical Oncology, 17, 2073-2080. [Google Scholar] [CrossRef] [PubMed]
[14] Shi, J., Lai, E.C., Li, N., et al. (2011) A New Classification for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Journal of Hepato-Biliary-Pancreatic Sciences, 18, 74-80. [Google Scholar] [CrossRef] [PubMed]
[15] Niu, Z.J., Ma, Y.L., Kang, P., et al. (2012) Transarterial Che-moembolization Compared with Conservative Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Using a New Classification. Medical Oncology, 29, 2992-2997. [Google Scholar] [CrossRef] [PubMed]
[16] 杨柳, 朱曦龄, 金帅, 等. 程氏分型对肝细胞癌伴门脉癌栓放疗预后的指导价值[J]. 肝癌电子杂志, 2020, 7(3): 7-11.
[17] 周存才, 张小芳, 魏小勇, 等. 对门静脉癌栓的新认识与新实践[J]. 中国肿瘤临床, 2022, 49(15): 764-768.
[18] 周俭, 樊嘉, 肖永胜. 肝细胞癌门静脉癌栓形成机制[J]. 实用肿瘤杂志, 2009, 24(5): 425-428.
[19] 谢国斌. 手术治疗原发性肝癌合并门静脉癌栓疗效的探讨[J]. 中国现代医学杂志, 2011, 21(8): 1046-1048+51.
[20] Fujikawa, T., Shiraha, H., Ueda, N., et al. (2007) Des-Gamma-Carboxyl Prothrombin-Promoted Vascular Endothelial Cell Proliferation and Migration. Journal of Biolog-ical Chemistry, 282, 8741-8748. [Google Scholar] [CrossRef] 
[21] Pote, N., Cauchy, F., Albuquerque, M., et al. (2015) Performance of PIVKA-II for Early Hepatocellular Carcinoma Diagnosis and Prediction of Microvascular Invasion. Journal of Hepatol-ogy, 62, 848-854. [Google Scholar] [CrossRef] [PubMed]
[22] Wang, X., Zhang, W., Liu, Y., et al. (2017) Diagnostic Value of Prothrombin Induced by the Absence of Vitamin K or Antagonist-II (PIVKA-II) for Early Stage HBV Related Hepato-cellular Carcinoma. Infectious Agents and Cancer, 12, 47. [Google Scholar] [CrossRef] [PubMed]
[23] Li, T., Yu, Y., Liu, J., et al. (2019) PIVKA-II Level Is Correlated to Development of Portal Vein Tumor Thrombus in Patients with HBV-Related Hepatocellular Carcinoma. Infectious Agents and Cancer, 14, 13. [Google Scholar] [CrossRef] [PubMed]
[24] Liu, Y., Wang, X., Jiang, K., et al. (2014) The Diagnostic Value of Tumor Biomarkers for Detecting Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombosis. Cell Bi-ochemistry and Biophysics, 69, 455-459. [Google Scholar] [CrossRef] [PubMed]
[25] Zhou, L., Jin, Y., Cui, Q.C., et al. (2013) Low Expression of PAI-2 as a Novel Marker of Portal Vein Tumor Thrombosis and Poor Prognosis in Hepatocellular Carcinoma. World Journal of Surgery, 37, 608-613. [Google Scholar] [CrossRef] [PubMed]
[26] Ye, L.Y., Chen, W., Bai, X.L., et al. (2016) Hypoxia-Induced Ep-ithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenviron-ment to Promote Metastasis. Cancer Research, 76, 818-830. [Google Scholar] [CrossRef] 

为你推荐